Literature DB >> 17709467

Influence of inoculum size on the selection of resistant mutants of Escherichia coli in relation to mutant prevention concentrations of marbofloxacin.

Aude Ferran1, Véronique Dupouy, Pierre-Louis Toutain, Alain Bousquet-Mélou.   

Abstract

We demonstrate using an in vitro pharmacodynamic model that the likelihood of selection of Escherichia coli mutants resistant to a fluoroquinolone was increased when the initial size of the bacterial population, exposed to fluoroquinolone concentrations within the mutant selection window, was increased.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17709467      PMCID： PMC2151440          DOI： 10.1128/AAC.00156-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  10 in total

1.  Mutant prevention concentrations of fluoroquinolones for clinical isolates of Streptococcus pneumoniae.

Authors:  J M Blondeau; X Zhao; G Hansen; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2001-02       Impact factor: 5.191

2.  Mutant prevention concentrations of ciprofloxacin for urinary tract infection isolates of Escherichia coli.

Authors:  Linda L Marcusson; Sara K Olofsson; Patricia Komp Lindgren; Otto Cars; Diarmaid Hughes
Journal:  J Antimicrob Chemother       Date:  2005-04-28       Impact factor: 5.790

3.  Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.

Authors:  Sara K Olofsson; Linda L Marcusson; Patricia Komp Lindgren; Diarmaid Hughes; Otto Cars
Journal:  J Antimicrob Chemother       Date:  2006-04-19       Impact factor: 5.790

4.  Mutant prevention concentration as a measure of antibiotic potency: studies with clinical isolates of Mycobacterium tuberculosis.

Authors:  Y Dong; X Zhao; B N Kreiswirth; K Drlica
Journal:  Antimicrob Agents Chemother       Date:  2000-09       Impact factor: 5.191

Review 5.  Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies.

Authors:  X Zhao; K Drlica
Journal:  Clin Infect Dis       Date:  2001-09-15       Impact factor: 9.079

6.  In vitro pharmacodynamic evaluation of the mutant selection window hypothesis using four fluoroquinolones against Staphylococcus aureus.

Authors:  Alexander A Firsov; Sergey N Vostrov; Irene Y Lubenko; Karl Drlica; Yury A Portnoy; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

7.  Prediction of the effects of inoculum size on the antimicrobial action of trovafloxacin and ciprofloxacin against Staphylococcus aureus and Escherichia coli in an in vitro dynamic model.

Authors:  A A Firsov; S N Vostrov; O V Kononenko; S H Zinner; Y A Portnoy
Journal:  Antimicrob Agents Chemother       Date:  1999-03       Impact factor: 5.191

8.  Predictors of effect of ampicillin-sulbactam against TEM-1 beta-lactamase-producing Escherichia coli in an in vitro dynamic model: enzyme activity versus MIC.

Authors:  A A Firsov; D Saverino; D Savarino; M Ruble; D Gilbert; B Manzano; A A Medeiros; S H Zinner
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

9.  Mutation rate and evolution of fluoroquinolone resistance in Escherichia coli isolates from patients with urinary tract infections.

Authors:  Patricia Komp Lindgren; Asa Karlsson; Diarmaid Hughes
Journal:  Antimicrob Agents Chemother       Date:  2003-10       Impact factor: 5.191

10.  Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.

Authors:  Stephen H Zinner; Irene Yu Lubenko; Deborah Gilbert; Kelly Simmons; Xilin Zhao; Karl Drlica; Alexander A Firsov
Journal:  J Antimicrob Chemother       Date:  2003-09-01       Impact factor: 5.790
  10 in total
  14 in total

1.  Pharmacokinetic/pharmacodynamic analysis of the influence of inoculum size on the selection of resistance in Escherichia coli by a quinolone in a mouse thigh bacterial infection model.

Authors:  Aude A Ferran; Anne-Sylvie Kesteman; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2009-06-01       Impact factor: 5.191

2.  Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Authors:  Maleck V Vasseur; Michel Laurentie; Jean-Guy Rolland; Agnès Perrin-Guyomard; Jérôme Henri; Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2014-01-06       Impact factor: 5.191

3.  Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.

Authors:  Anne-Sylvie Kesteman; Aude A Ferran; Agnès Perrin-Guyomard; Michel Laurentie; Pascal Sanders; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Antimicrob Agents Chemother       Date:  2009-09-08       Impact factor: 5.191

4.  Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection.

Authors:  Aude A Ferran; Pierre-Louis Toutain; Alain Bousquet-Mélou
Journal:  Vet Microbiol       Date:  2010-09-15       Impact factor: 3.293

5.  Testing the mutant selection window hypothesis with Escherichia coli exposed to levofloxacin in a rabbit tissue cage infection model.

Authors:  W Ni; X Song; J Cui
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-09-14       Impact factor: 3.267

Review 6.  Application of PK/PD Modeling in Veterinary Field: Dose Optimization and Drug Resistance Prediction.

Authors:  Ijaz Ahmad; Lingli Huang; Haihong Hao; Pascal Sanders; Zonghui Yuan
Journal:  Biomed Res Int       Date:  2016-02-16       Impact factor: 3.411

7.  Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.

Authors:  Maleck V Vasseur; Marlene Z Lacroix; Pierre-Louis Toutain; Alain Bousquet-Melou; Aude A Ferran
Journal:  PLoS One       Date:  2017-08-04       Impact factor: 3.240

8.  Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies.

Authors:  Guillaume Lhermie; Farid El Garch; Pierre-Louis Toutain; Aude A Ferran; Alain Bousquet-Mélou
Journal:  PLoS One       Date:  2015-10-27       Impact factor: 3.240

9.  Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.

Authors:  Guillaume Lhermie; Aude A Ferran; Sébastien Assié; Hervé Cassard; Farid El Garch; Marc Schneider; Frédérique Woerhlé; Diane Pacalin; Maxence Delverdier; Alain Bousquet-Mélou; Gilles Meyer
Journal:  Front Microbiol       Date:  2016-03-02       Impact factor: 5.640

10.  Pharmacokinetic-Pharmacodynamic Modeling of Enrofloxacin Against Escherichia coli in Broilers.

Authors:  KaNa Sang; HaiHong Hao; LingLi Huang; Xu Wang; ZongHui Yuan
Journal:  Front Vet Sci       Date:  2016-01-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.